



ASX ANNOUNCEMENT

Lumos Diagnostics Expands Distribution Partnership with Regional Health Care Group, Henry Schein's Medical Business in Australia and New Zealand, for FebriDx®

Rapid point-of-care test available to health care practitioners in Australia and New Zealand

MELBOURNE, Australia (4 July 2024) – Lumos Diagnostics (ASX: LDX), (“Lumos”) a leader in rapid, point-of-care (POC) diagnostic technologies, has signed an agreement with Regional Health Care Group (RHCG), a Henry Schein company in Australia and New Zealand for the FebriDx® point-of-care test. The agreement further expands the distribution of FebriDx through Henry Schein’s Medical business to include Australia and New Zealand. RHCG is a part of Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners.

“At Henry Schein, our goal is to help health care professionals enhance efficiencies through practice care so they can focus on delivering quality patient care. We are therefore delighted to expand our distribution of FebriDx beyond Portugal, Spain, the Netherlands, the United Kingdom, and the United States to now include Australia and New Zealand,” said Mike Covey, Henry Schein Vice President – APAC Region and Managing Director, Australia.

FebriDx® is a rapid POC test to differentiate a viral from bacterial acute respiratory infection. FebriDx delivers results after 10 minutes from fingerstick blood and can be used to help rapidly and accurately manage infectious patients in Primary Care, Urgent Care, Emergency Dept, Paediatric and other Outpatient settings. Regional Health Care Group will sell the FebriDx test throughout Australia and New Zealand with sales and marketing activities commencing immediately.

“It is great to see the increased interest in our FebriDx test from one of the world’s largest distributors of healthcare and medical products,” said Doug Ward, CEO of Lumos Diagnostics. “Henry Schein has been a terrific and supportive partner for Lumos across Europe. With our recent U.S. launch and the growing commercial interest in FebriDx, we are now preparing production of FebriDx to meet the anticipated growing demand for the product, to support our customers. It is very exciting to have Henry Schein as part of this strategy with their expanded distribution coverage for FebriDx in the Australian and New Zealand markets.”

This announcement has been approved by the Lumos Disclosure Committee.

For personal use only



About Lumos Diagnostics

Lumos Diagnostics specializes in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

About Henry Schein, Inc.

Regional Health Care Group, Henry Schein's Medical business in Australia and New Zealand, is part of Henry Schein, Inc. (Nasdaq: HSIC), a solutions company for health care professionals powered by a network of people and technology. With more than 25,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. The Company's Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.

Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein corporate brand products in our distribution centers. A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 33 countries and territories.

For more information, visit Henry Schein at the company's corporate website

<https://investor.henryschein.com/aboutus> or at <https://henryschein.com.au/about-us> for Australia.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

For personal use only



Lumos - Media Contact:

Haley Chartres – Australia
H^CK Director
haley@hck.digital
+61 423 139 163

Lumos - Investor Contact:

Jane Lowe
Managing Director, IR Department
ir@lumosdiagnostics.com
+61 411 117 774

Lumos - Company Registered Office:

Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205, Australia
+61 3 9087 1598

Henry Schein – Media Contact:

Stefanie Fleige
Director, Corporate Media Relations – EMEA
Stefanie.fleige@henryschein.de
+49 172 643 3548

For personal use only